La Jolla Pharmaceutical Company (NASDAQ: LJPC) is 1.55% higher on its value in year-to-date trading and has touched a low of $3.36 and a high of $9.38 in the current 52-week trading range. The LJPC stock was last observed hovering at around $3.94 in the last trading session, with the day’s gains setting it 1.21% off its average median price target of $12.00 for the next 12 months. It is also 74.25% off the consensus price target high of $20.00 offered by 2 analysts, but current levels are -28.75% lower than the price target low of $4.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $5.15, the stock is 22.53% and 19.10% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 32.35 million and changing 30.71% at the moment leaves the stock 7.38% off its SMA200. LJPC registered -34.33% loss for a year compared to 6-month gain of -4.83%. The firm has a 50-day simple moving average (SMA 50) of $4.43 and a 200-day simple moving average (SMA200) of $4.20.
The stock witnessed a -13.02% loss in the last 1 month and extending the period to 3 months gives it a -3.67%, and is -3.43% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.38% over the week and 5.70% over the month.
La Jolla Pharmaceutical Company (LJPC) has around 90 employees, a market worth around $108.63M and $29.70M in sales. Distance from 52-week low is 53.42% and -45.10% from its 52-week high. The company has generated returns on investments over the last 12 months (183.30%).
La Jolla Pharmaceutical Company (LJPC) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for La Jolla Pharmaceutical Company (LJPC) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.30, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
La Jolla Pharmaceutical Company is expected to release its quarterly report on 05/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.35 with sales reaching $10.89M over the same period.The EPS is expected to grow by 45.20% this year, but quarterly earnings will post 44.70% year-over-year. Quarterly sales are estimated to grow 50.20% in year-over-year returns.
La Jolla Pharmaceutical Company (LJPC) Top Institutional Holders
100 institutions hold shares in La Jolla Pharmaceutical Company (LJPC), with 398.94k shares held by insiders accounting for 1.46% while institutional investors hold 89.30% of the company’s shares. The shares outstanding are 27.37M, and float is at 26.98M with Short Float at 10.85%. Institutions hold 88.00% of the Float.
The top institutional shareholder in the company is Tang Capital Management, LLC with over 9.41 million shares valued at $37.9 million. The investor’s holdings represent 34.35% of the LJPC Shares outstanding. As of Sep 29, 2020, the second largest holder is RTW Investments LP with 2.4 million shares valued at $9.65 million to account for 8.75% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.44 million shares representing 5.26% and valued at over $5.81 million, while Vanguard Group, Inc. (The) holds 3.89% of the shares totaling 1.07 million with a market value of $4.3 million.
La Jolla Pharmaceutical Company (LJPC) Insider Activity
A total of 41 insider transactions have happened at La Jolla Pharmaceutical Company (LJPC) in the last six months, with sales accounting for 0 and purchases happening 41 times. The most recent transaction is an insider purchase by TANG KEVIN C, the company’s Director. SEC filings show that TANG KEVIN C bought 126,665 shares of the company’s common stock on Sep 09 at a price of $4.03 per share for a total of $0.51 million. Following the purchase, the insider now owns 9.41 million shares.
La Jolla Pharmaceutical Company disclosed in a document filed with the SEC on Sep 08 that RAMSAY DAVID A (Director) bought a total of 1,000 shares of the company’s common stock. The trade occurred on Sep 08 and was made at $3.83 per share for $3830.0. Following the transaction, the insider now directly holds 48000.0 shares of the LJPC stock.
Still, SEC filings show that on Sep 08, TANG KEVIN C (Director) acquired 84,152 shares at an average price of $3.90 for $0.33 million. The insider now directly holds 9,278,825 shares of La Jolla Pharmaceutical Company (LJPC).
La Jolla Pharmaceutical Company (LJPC): Who are the competitors?
The company’s main competitors (and peers) include Intercept Pharmaceuticals Inc. (ICPT) that is trading -72.89% down over the past 12 months. BioCryst Pharmaceuticals Inc. (BCRX) is 136.91% up on the 1-year trading charts. Short interest in the company’s stock has fallen -8.53% from the last report on Nov 12, 2020 to stand at a total of 3.18 million short shares sold with a short interest ratio of 15.05.